Percutaneous Implantation of Autologous Bone Marrow Osteoprogenitor Cells as Treatment of Bone Avascular Necrosis Related to Sickle Cell Disease
Philippe Hernigou*, 1, Gilsasio Daltro2, Paolo Filippini1, Martin Mukisi Mukasa3, Olivier Manicom3
Identifiers and Pagination:Year: 2008
First Page: 62
Last Page: 65
Publisher ID: TOORTHJ-2-62
Article History:Received Date: 03/3/2008
Revision Received Date: 26/3/2008
Acceptance Date: 07/4/2008
Electronic publication date: 25/4/2008
Collection year: 2008
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/license/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
The treatment of bone a vascular necrosis is a big challenge considering the youthfulness of the patients involved by necrosis in sickle cell disease and the importance of the generated disability. A vascular osteonecrosis is an epiphysis pathology which could be treated by joint replacement with success, however, multiple surgical procedures are mostly necessary during the patient’s life with a hazardous long term functional results. The treatment by autologous bone marrow grafting is an effective alternative which preserve the native joint. Using this mini-invasive high technology surgical treatment in early stages, a joint replacement could be avoided in many patients.